SUN PHARMACEUTICAL INDUSTRIES LIMITED (NSE : SUNPHARMA) Q4 FY23 Earnings Concall dated May. 26, 2023. Corporate Participants: Abhishek Sharma -- Head of
SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUNPHARMA) Q4 FY23 Earnings Concall Transcript
Categories
Healthcare
Sequent Scientific Limited Q4 FY23 Earnings Conference Call Insights
Key highlights from Sequent Scientific Limited (SEQUENT) Q4 FY23 Earnings Concall Q&A Highlights: [00:14:02] Vishwas asked about the utilization of the API
Earnings Summary Of Fortis Healthcare Limited For Q4 FY23
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. With a strong network of hospitals and diagnostics centers,
Divi’s Laboratories Limited Q4 FY23; Net Profit Down By 64%
Divi's Laboratories Limited reported Total Income for Q4 FY23 of ₹2,016.92 Crore down from ₹2,570.83 Crore year on year, a decline of
Divi’s Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE: DIVISLAB) Q4 FY23 Earnings Concall dated May. 20, 2023 Corporate Participants: M. Satish Choudhury -- Company Secretary and Chief Investor
Zydus Lifesciences Ltd (ZYDUSLIFE) Q4 FY23 Earnings Concall Transcript
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) Q4 FY23 earnings concall dated May. 18, 2023 Corporate Participants: Ganesh Nayak -- Executive Director Sharvil Patel -- Managing Director Nitin
Shalby Ltd Q4FY23 results out, net profit grows by 40%
Shalby Ltd reported Total revenue for Q4 FY23 of ₹199 Crore, up from ₹163 Crore year on year depicting a growth of
Shalby Ltd Q4FY23 results out, revenue grows by 22%
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of
Zydus Wellness Ltd (ZYDUSWELL) Q4 FY23 Earnings Concall Transcript
Zydus Wellness Ltd (NSE: ZYDUSWELL) Q4 FY23 earnings concall dated May. 17, 2023 Corporate Participants: Tarun Arora -- Chief Executive Officer and Whole Time
Max Healthcare Inst 4Q23; 85% Growth in Profit
Max Healthcare Institute’s revenue in Q4FY23 rose 26% to ₹ 1,637 crores. Consolidated Profit After Tax came at ₹ 320 crores in
Cipla Limited (CIPLA) Q4 FY23 Earnings Concall Transcript
Cipla Limited (NSE:CIPLA) Q4 FY23 Earnings Concall dated May. 12, 2023. Corporate Participants: Ajinkya Pandharkar -- Investor Relations Umang Vohra -- Managing Director and Global Chief
Procter & Gamble Hygiene & Health Care Q4FY23; 3% Fall in Profits
Procter & Gamble Hygiene & Health Care’s total income in Q4FY23 fell 8% to ₹ 898 crores. Consolidated Profit After Tax came
Jyothy Laboratories Limited (JYOTHYLAB) Q4 FY23 Earnings Concall Transcript
Jyothy Laboratories Limited (NSE:JYOTHYLAB) Q4 FY23 Earnings Concall dated May. 03, 2023. Corporate Participants: Sanjay Agarwal -- Chief Financial Officer M R Jyothy -- Managing Director
Aarti Drugs Limited (AARTIDRUGS) Q4 FY23 Earnings Concall Transcript
Aarti Drugs Limited (NSE:AARTIDRUGS) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Adhish Patil -- Chief Financial Officer Harshit M. Savla -- Joint Managing
Dhampur Bio Organics Ltd (DBOL) Q4 FY23 Earnings Concall Transcript
Dhampur Bio Organics Ltd (NSE:DBOL) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Mr. Navin Agrawal -- Head of Institutional Equities Nalin
Glenmark Pharmaceuticals: An Uphill Battle
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Sequent Scientific Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API business, the
The Revival of Amrutanjan Healthcare Limited
Amrutanjan’s flagship yellow headache balm is possibly its most successful product. It is also among the first products that the company launched.
Earnings Summary Of Krishna Institute of Medical Sciences Limited For Q3 FY23
KIMS is known for providing high-quality healthcare services across various specialties such as cardiology, oncology, orthopedics, neurology, and gastroenterology. The company's hospitals
Star Health & Allied Insurance Limited Q3FY23
With a market share of 15.8 percent in the Indian health insurance industry in FY21 and leading in the lucrative retail health
Rainbow Children’s Medicare Q3FY23 Earnings
An Indian hospital network with many specialties in paediatrics, obstetrics, and gynaecology is run by Rainbow Children's Medicare Limited. The business provides